|Name||Indication||Clinical Trial Phase||Study Title|
|HLX10+HLX07||phase II||Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors|
|HLX10+HLX07||phase II||A Randomized, Open-Label, Multicenter, Phase II Study of HLX07 (Anti-EGFR Antibody) In Combination With HLX10 (Anti-PD-1 Antibody) With or Without Chemotherapy Versus HLX10 With Chemotherapy in First Line Recurrent or Metastatic Squamous Non-Small Cell Lung Cancer.|
First subject has been doesd in the international multi-centre phase 3 clinical trial for HLX14 in China for the treatment of postmenopausal osteoporosis in women with high fracture risks.
|HLX10 + chemotherapy||phase II||
A Clinical Study to Evaluate Efficacy and Safety of HLX10 Combined With Albumin-Bound Paclitaxel in Patients With Advanced Cervical Cancer Who Have Progressive Disease or Intolerable Toxicity After First-Line Standard Chemotherapy